Pear Therapeutics to go public via merger with Thimble Point SPAC

Pear Therapeutics, a developer of prescription digital therapeutics, has agreed to go public via a merger with Thimble Point Acquisition Corp, a blank check company whose management team is associated with the Pritzker Vlock Family Office.

Share this